Icon times
Dr Reddy's Laboratories Stock Fundamental Analysis - Financial Results & Equity Research | Investyadnya Stock-o-Meter

Dr. Reddy's Laboratories

CompanyOver

 / 
error iconThis ratio is already added in the table

About

Promoted by Late Dr K Anji Reddy, Reddy Labs offers a portfolio of pharma generics, API & custom pharma services, biosimilars & differentiated formulations with its headquarters in Hyderabad, Telangana. Company has 3 divisions. Company derives 81% of revenue from global generics,17% from Pharma Service & Active Ingredients & 2% Proprietary Products. Company has strong presence in North America, Europe, India & other emerging markets. Company is among the top 3 domestic manufactures of API

Highlights

Performing rate for the company

Price Chart (Only Standalone)

Track the companies of Group.

Relaince Group

Sector: Refineries

Market Price

2,529.50

Market Cap(₹Cr.)

2,529.50

-90.00

Quarterly Results ( Figures in Rs. Crores.)

No Data is available.

Profit & Loss ( Figures in Rs. Crores.)

No Data is available.

Balance Sheet ( Figures in Rs. Crores.)

No Data is available.

Cash Flows ( Figures in Rs. Crores.)

No Data is available.

Historical Growths

Compounded Sales Growth
Compounded Profit Growth
Compounded Expense Growth
Stock Price CAGR
Sales Growth Profit Growth Expense Growth Stock Price CAGR

Ratios ()

No Data is available.

Major Shareholders

No Data is available.

Shareholders more than 1%

No Data is available.

Fund houses invested in the stock (Figures in % Equity Capital )

No Data is available.

Corporate Action

No Data is available.
No Data is available.
No Data is available.
No Data is available.

Documents

Presentation & Earning Calls

Annual Reports

Credit Rating

No document is available
No document is available
No document is available
No document is available.

Overview

Dr. Reddy’s Laboratories Limited commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas. The company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and on the New York Stock Exchange in the United States.

Business area of the company

The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations.

Products

Generics
Over-the-counter
APIs (Active Pharmaceutical Ingredients)
Biologics
Differentiated Formulations
Core Businesses
Pharmaceutical services & active ingredients
Global leader in integrated development, manufacturing and supply of APIs.
Contract research, development and manufacturing services.
Global Generics
Finished dosage businesses in distribution-driven unbranded as well as detailing-driven branded markets.
North America, Europe, India, China, Russia & CIS countries are key markets in this segment.
Proprietary Products
Developing differentiated formulations that present significantly enhanced benefits in terms of efficacy, ease of use, and the resolution of unmet patient needs.
Awards & Recognitions
India’s Best Managed Boards by Mint and Aon Hewitt and by Economic Times and Hays in their respective studies.
India’s Best Companies to Work For in the Biotechnology and Pharmaceuticals sector by Great Place To Work Institute.
‘Best Places to Work’ in 2017 in New Jersey by NJBIZ.
Global Generics & Biosimilar Award 2018 for CSR initiative of the year
India Pharma Corporate Social Responsibility (CSR) programme of the year Award 2018 by Department of Pharmaceuticals, Government of India.
Dr. Reddy’s ranked among the top 10 in the Forbes China 2018 list of leading Indian Companies in China.
Dr. Reddy’s inclusion in the 2019 Bloomberg Gender-Equality Index.
Global Generics & Biosimilars Award 2019: API supplier of the Year at the 6th Annual Global Generics & Biosimilars Awards.
Winner of Golden Peacock International Award for Sustainability for the year 2019.
Milestones
1984: The birth of a dream
1991: From molecules to affordable medicines
1995: Expanding to reach patients in other countries
2001: Spreading wings globally
2007: Accelerating access to expensive therapies
2010: From medicines to health
2012: Strengthening capabilities
2014: Re-dedicating to patient-centricity
2015: Dr. Reddy’s Laboratories signs commercialization deal with Hatchtech
2016: Dr. Reddy’s completes acquisition of product portfolio from TEVA
2017: Dr. Reddy's expands commercial operations in Europe
2018: Dr. Reddy's Laboratories announces the launch of Tetrabenazine Tablets in the U.S. Market
2019: Dr. Reddy’s Laboratories enters Nutrition Segment with Celevida in India
2020: Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets


In 1984 a company whose motto is Good Health Can't-Wait started its journey by laying its first stone in Hyderabad Telangana. Dr Reddy is an Indian multinational pharmaceutical company founded by Anji Reddy. They started their journey as a drug supplier in the Indian subcontinent. Still, They later expanded their horizons to unregulated markets, which helped them gain profits, fame, and approval from the FDA to enter the bigger regulated ones like the USA and UK. Within a year, Reddy's became the first Indian company to export the active ingredients for pharmaceuticals to Europe. Crossing the three-year mark, Dr. Reddy entered into the manufacturing of pharma drugs. As of the year 2007, Dr. Reddy had seven plants producing active pharma ingredients, out of which five were in India, and two of them were in the UK. With over 190 medications, 60 active ingredients, Dr. Reddy's net income stands strong at 270 million USD. Major markets they operate in are the USA, India, Russia & CIS countries, and Europe.

SERVICES

They are into three different businesses across the globe.

  1. Pharmaceutical Services and Active Ingredients

  2. Global Generics

  3. Proprietary Products

Apart from APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations Dr. Reddy,s major med areas include

Gastrointestinal 
Cardiovascular
 Diabetology
 Oncology
 Pain Management 
Anti-infective
Dermatology
Depression


MERGERS AND ACQUISITIONS
In 1999 Dr. Reddy joined forces with American Remedies Ltd. to stand more robust in the Indian med market.
To expand itself in the European market in 2002, Reddy's started its European operations by acquiring two pharmaceutical firms in the United Kingdom. It was the addition of BMS Laboratories and its 100% owned subsidiary, Meridian UK.
In 2002 Entering into the research world, Reddy established a wholly-owned subsidiary Aurigene Discovery Technologies, a contract research company.
In 2004 they acquired Trigenesis Therapeutics Inc a US-based private dermatology company.
With the growing expansion, Reddy bought Betapharm Arzneimittel for a whopping 480 million USD in march 2006.
In 2015, Dr. Reddy's Laboratories bought the established brands of Belgian drugmaker UCB SA in South Asia for 128.38 million USD.

MILESTONES
By 2000 Dr. Reddy was India’s third-largest pharmaceutical company.
2001 brought some ground turning milestones for Dr. Reddys. They were the first non-japanese pharmaceutical company in the Asia Pacific region to place in the New York Exchange listing.
2001 being the lucky one, Dr. Reddy became the first pharma company in India to launch the generic drug fluoxetine with 180 days exclusivity in the US.
In September 2016, Dr. Reddy’s launched “Purple Health” in India, a patient-centric platform to deliver solutions that address patients’ unmet needs.
In 2020 The company agreed to conduct final-stage trials of Russia's Gam-COVID-Vac vaccine (trade name Sputnik V) in India. They plan to distribute up to 100 million doses after regulatory clearances and successful conduct of the trials.
ACHIEVEMENTS
Best CSR & Sustainability Practices 2008 – 9th International Conference on Corporate Governance & Sustainability
In 2012 Dr. K. Anji Reddy was honoured with the Lifetime Achievement award in Britain.
IN 2016 Excellence in Patient Engagement and Excellence in Supply Chain & Logistics Management by Indian pharma awards to Dr. Reddy.
Dr. Reddy’s Laboratories Ltd has bagged the Year award’s API Supplier at the 6th Annual Global Generics & Biosimilars Awards in Frankfurt, Germany.
Best Company in Class - HDMA Annual Leadership Forum (North America)
5 HR Awards at World HRD Congress




ABOUT INVEST YADNYA

Invest Yadnya is a company that educates and simplifies the concepts of personal finance for each individual. We have amalgamated technology with financial planning expertise to help an individual meet their financial objectives. We invest time, money, and knowledge to build financial literacy in India.


We offer various products and services including, Personalized Financial Planning, Stock Market Analysis with eBook Subscriptions, Simplest Income Tax Information Bank, Comprehensive Mutual Fund Reviews, and Do-It-Yourself Financial Planning.


Invest Yadnya should be a choice because it offers unbiased and transparent stock analysis reports. Our work is knowledge-based and has specific proprietary methodologies and a stock research framework. We continuously keep updating our data and have the latest information available. 


We help our clients do extensive research on 950+ companies, including Dr. Reddy stock analysis. You can find the latest Dr. Reddy stock price on Invest Yadnya. We also provide our clients with the Dr Reddy balance sheet. It helps the clients understand the financial position of the company before making any investment decisions. The Dr. Reddy analysis helps the investors identify the intrinsic worth of the security. Dr. Reddy results provide a summary of how the business incurs revenues and expenses. We also offer our clients with Dr. Reddy share price graphs.


Detailed Stock Articles on Dr Reddy's Laboratories vs Cipla Stock Comparison: Part 1 & Part 2 are provided on our website, which offers an in-depth Dr Reddy stock review. It gives an investor a sense of whether the company is growing, stable or deteriorating. This helps investors make a viable investment decision with a thorough discussion on Dr. Reddy annual report.

Invest Yadnya offers numerous resources for Dr. Reddy share analysis. With the available Dr Reddy's Laboratories financial statements, price chart, ratios, etc., get a detailed analysis of the company. With Invest Yadnya’s available resources, get an overview of the company, both from the qualitative and financial perspective. The investors shall make a viable investment decision depending on your risk profile & other economic factors.

Dr Reddy's Laboratories analysis gives the clients a better understanding of the company’s EPS, Debt-Equity Ratio etc. It helps clients take the first step in choosing which companies to invest in. 

Dr Reddy's Laboratories’ economic analysis helps allocate the equity in the Portfolio of an investor to add to its favourable returns.

To find the Dr Reddy Performance analysis & Dr Reddy stock chart, subscribe to our Equity Research and Stock Fundamental Analysis Tool, Stock-O-Meter.

Our website has information about 113 other Pharmaceuticals & Drugs companies that give insight into its financials. Companies include Divis Laboratories, Cipla, Sun Pharmaceutical Industries, Biocon, Aurobindo Pharma, Lupin, Torrent Pharmaceuticals, Cadila Healthcare, Abbott India, Glaxosmithkline Pharmaceuticals & many more.

Brands Of Dr. Reddy's Laboratories

Brands Of Dr. Reddy's Laboratories

undefined

Comment

Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya